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GALVmed, a public private partnership established to promote commercialization and pro-poor access to 
animal vaccines and diagnostics, is establishing the commercial distribution and delivery of the infection and 
treatment vaccine for East Coast fever based on an ILRI-produced vaccine, ILRI protocols for large-scale 
production and ILRI technical inputs into registration documents.   
Over the past decade, numerous public-private partnerships for human health vaccines, diagnostics and medicines 
(e.g. GAVI, Medicines for Malaria) have been established to bridge the gap in product development and delivery for the 
poor. In 2005, ILRI with funding from DFID, supported the establishment of the first animal health public-private 
partnership, the Global Alliance for Livestock Vaccines and Veterinary Medicines (GALVmed) – see www.galvmed.org 
for further details. GALVmed has secured major funding in 2008 to launch flagship products, the first of which is the 
ILRI-produced infection and treatment (ITM) vaccine for East Coast fever. The production, distribution and delivery of 
ITM will require many actors. The first outcome is for GALVmed to establish the commercialization process; GALVmed 
is working with AU-IBAR and PANVAC to facilitate the registration of the vaccine in several East African countries (see 
http://www.galvmed.org/news/news10.php).  Subsequent outcomes will be in the development of distribution and 
delivery chains across East Africa and the establishment of alternative vaccine producers. 
Two research output targets provide the basis for GALVmed to be able to establish a commercialization process for 
ITM production, distribution and delivery. The first was an output target in 2007 (MTP 2007-9) “a protocol developed 
that is suitable for large-scale production and distribution of ECF-ITM vaccine”. The second was an output target in 
2008 (MTP 2008-10) for incorporating these protocols in ECF vaccine and licensing documentations.  
Based on the 2007 protocols, ILRI produced in 2008, 1 million doses of ITM vaccine that allowed GALVmed to move 
forward in planning a commercial distribution and delivery network for ITM, getting it funded and engaging commercial 
partners. GALVmed was able to secure funding for this commercial development in 2008 and launched a call for 
prospective commercial distributors (see attached evidence documents 1&2). GALVmed was also, with ILRI support, 
able to develop a registration dossier for the ILRI produced vaccine in 2008 (see attachment 3), for which registration 
has already been secured in Malawi and has been applied for and is pending in Tanzania, Uganda and Kenya. This 
GALVmed outcome will lead directly to a next level of outcome in which GALVmed will be supporting emerging 
commercial distributors in eastern and southern Africa as part of their funded program and consistent with the call for 
commercial distributors.  
Linking vaccine research outputs to commercial distribution and delivery organizations (both private and public) is 
difficult in developing countries, particularly for products targeting poor farmers and in regions such as sub-Saharan 
Africa. Linking research outputs from ILRI through a public-private partnership such as GALVmed, provides a 
replicable model for enabling faster and more effective distribution and delivery of the products of research to the 
ultimate clients. This is an essential innovation in enabling the research investments of ILRI and others to have more 
widespread impact.  
Evidence provided to the CGIAR: 
1. Attachment 1: GALVmed funding for commercial distribution 
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2. Attachment 2: GALVmed proposal call for distribution 
3. Attachment 3: Registration dossier 
 
 
